February 2022 decisions news release

Medicines for lung cancer due to previous asbestos Medicines for lung cancer due to previous asbestos exposure and for a severely disabling muscle wasting disease among six accepted for use by Scottish Medicines Consortiumaccepted for use by Scottish Medicines Consortium

Advice on six new medicines for use in conditions including a rare lung cancer caused by occupational exposure to asbestos and also for a severely disabling muscle wasting disease has today (Monday 7 February) been published by the Scottish Medicines Consortium (SMC).